Lex, you have been here a long time. You know how much money was poured into CardioCell and Vascucell by the company and holders - you can't honestly tell me that selling it for that amount was a good deal/outcome for investors? Better than the $0 received for immunotherapy but that was always a gamble where as this was proven to be good tech.
Should have licensed or partnered it from day one, which is likely to be the case with TAVR if it gets up, so a good lesson learned, even if a colossally expensive one. Ah well, isn't hindsight great, even if useless.
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-188
-
- There are more pages in this discussion • 102 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.30 |
Change
-0.650(5.44%) |
Mkt cap ! $238.8M | |||
| Open | High | Low | Value | Volume |
| $11.71 | $11.83 | $11.24 | $346.8K | 29.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 90 | $11.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.50 | 50 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |